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Mycobacteria have a unique cell wall consisting of
mycolic acids, very-long-chain lipids that provide
protection and allow the bacteria to persist within
human macrophages. Inhibition of cell wall biosyn-
thesis is fatal for the organism and a starting point
for the discovery and development of novel antibi-
otics. We determined the crystal structures of KasA,
a key enzyme involved in the biosynthesis of long-
chain fatty acids, in its apo-form and bound to the
natural product inhibitor thiolactomycin. Detailed
insights into the interaction of the inhibitor with
KasA and the identification of a polyethylene glycol
molecule thatmimicsa fatty acid substrateof approx-
imately 40 carbon atoms length, represent the first
atomic view of a mycobacterial enzyme involved in
the synthesis of long-chain fatty acids and provide
a robust platform for the development of novel thio-
lactomycin analogs with high affinity for KasA.
INTRODUCTION
Tuberculosis (TB), an infectious disease caused by Mycobacte-
rium tuberculosis, remains one of the leading causes of death in
the world. It is estimated that tuberculosis causes 8.8 million new
infections and 1.6 million deaths each year (WHO, 2007). The
rapid emergence of new strains, which are resistant to most
of the known antibiotics, has increased the complexity of TB
treatment. Patients infected with multi-drug-resistant strains of
M. tuberculosis (MDR-TB) require a longer, more costly thera-
peutic regimen (Dye et al., 2002). In addition, the recent appear-
ance of strains that are resistant to both first- and second-line
antibiotics (extensively drug-resistant TB, XDR-TB), represents
a severe threat because these strains are virtually untreatable
(Jain and Mondal, 2008). Consequently, it is important to identify
new drug targets and develop new chemotherapeutics that
circumvent existing drug-resistance mechanisms.
The mycobacterial cell wall is essential for the pathogen’s
survival. It is lipid rich and highly impermeable, and thereby
provides protection from many antibiotics and allows the bacteria
to persist and to proliferate in macrophages (Daffe and Draper,
1998; Yuan et al., 1998). Mycolic acids, which are long-chain1004 Structure 17, 1004–1013, July 15, 2009 ª2009 Elsevier Ltd Alla-alkyl-b-hydroxy fatty acids, constitute up to 60% of the cell
wall and are mainly responsible for the low permeability of the
waxy cell envelope (Asselineau and Lederer, 1950; Barry et al.,
1998). Unlike other bacteria, mycobacteria require two distinct
fatty-acid synthesis pathways to generate these long-chain fatty
acids: the mammalian-like FAS-I and the bacteria-like FAS-II
pathway (Kremer et al., 2000). The large multifunctional polypep-
tide complex within the FAS-I pathway is capable of de novo fatty
acid synthesis and generates fatty acids with a chain length of
C14-16 (Smith et al., 2003). These short fatty acids are transferred
to the FAS-II system, where they are elongated to fatty acids up to
56 carbons in length and serve as precursors for mycolic acids
(Kremer et al., 2002; Lu et al., 2004). In this pathway, an acyl
carrier protein (AcpM) shuttles the growing acyl chain between
discrete monofunctional enzymes that catalyze the individual
steps (Figure 1) (Campbell and Cronan, 2001). Growing evidence
points to a direct interaction of FAS-II enzymes with each other in
interconnected specialized complexes that are essential for
mycobacterial survival (Kremer et al., 2003; Veyron-Churlet
et al., 2005; Veyron-Churlet et al., 2004). The molecular basis
for these interactions, however, remains sketchy, and moreover
the capability of mycobacterial enzymes to interact with and effi-
ciently transfer the extremely long hydrophobic fatty acids from
one protein to the next within a cytosolic environment is not
understood.
KasA, the mycobacterial b-ketoacyl ACP synthase I, is an
important key enzyme within the FAS-II system. It catalyzes
the condensation between malonyl-AcpM and the growing
acyl chain via a ping-pong mechanism, the first of four steps in
the fatty acid elongation cycle (Figure 1). In a first step, the acyl
chain is transferred to the active-site cysteine, resulting in an
acylated KasA intermediate. Subsequently, the acyl chain is
elongated by two carbon atoms derived from the second
substrate malonyl-AcpM in a condensation reaction with the
KasA intermediate (Kremer et al., 2002). KasA has been shown
to be essential in mycobacteria: conditional depletion of KasA
induces cell lysis (Bhatt et al., 2005) and transposon-site hybrid-
ization has demonstrated that KasA is essential for cell growth
(Sassetti et al., 2003).
Inhibitors of FAS-II enzymes, with the first-line antibiotic isoni-
azid that targets InhA as the most prominent example, impair the
integrity of the cell wall and thereby act as bactericidal agents
(Slayden et al., 1996). The natural product inhibitor thiolactomy-
cin (TLM) is a promising lead compound for the development of
potent FAS-II inhibitors. TLM has favorable physicochemicalrights reserved
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Structure of M. tuberculosis KasAFigure 1. The FAS-II Pathway in M. tuber-
culosis
In M. tuberculosis, the FAS-II pathway elongates
the C18+ acyl-CoAs from the type I pathway to
C54-C56 fatty acids. The pathway is primed by
the CoA-dependent b-ketoacyl-AcpM synthase
FabH, which condenses the acyl-CoA with
malonyl-AcpM to generate a b-ketoacyl-AcpM.
The b-ketoacyl-AcpM is converted into a saturated
enoyl-AcpM by the sequential actions of a b-
ketoacyl-AcpM reductase (MabA), a dehydrase
and a trans-2-enoyl-AcpM reductase (InhA).
Subsequent rounds of elongation are initiated by
either the KasA or KasB b-ketoacyl-AcpM syn-
thases. KasA is thought to be responsible for the
early rounds of fatty acid elongation, whereas
KasB might be involved in later steps of mycolic
acid biosynthesis (Kremer et al., 2000). Also
shown is the malonyl-CoA AcpM transacylase
(FabD) responsible for the synthesis of malonyl-
AcpM.properties, is effective in mouse infection models, and has been
shown to inhibit the mycobacterial b-ketoacyl synthases KasA
and KasB, with KasA being the most sensitive (Kremer et al.,
2000; Schaeffer et al., 2001). Recent kinetic studies revealed
that TLM binds to both the free enzyme and the acylated form
of KasA (C.A.M. et al., unpublished data). Furthermore, it prefer-
entially binds to the acyl-enzyme intermediate and shows a slow
binding step during the inhibition reaction, which plays a crucial
role for the in vivo activity of the compound.
Here, we describe the first structures of M. tuberculosis KasA.
Active KasA was obtained through overexpression in Mycobac-
terium smegmatis as an expression host. Because the inhibitor
can bind to the apo form as well as the acylated form of the
enzyme, we solved binary complexes of TLM bound to KasA
using the acyl-enzyme mimic C171Q KasA and the wild-type
enzyme. The structures provide detailed insight into the interac-
tion of TLM with KasA and facilitate a molecular explanation for
the preferential binding to the acylated form of KasA. The pres-
ence of bound polyethylene glycol (PEG) molecules delineate
for the first time how a long-chain fatty acid is accommodated
in the acyl binding channel, and suggest how the substrate is effi-
ciently transferred from one protein to the next within the FAS-II
system.
RESULTS
Overall Description of the KasA Structure
In order to evaluate the interactions of TLM with KasA as a plat-
form for rational inhibitor design and to explore the molecular
basis for the preferential binding of TLM to acyl-KasA, we deter-
mined the X-ray structures of wild-type KasA and the acyl enzyme
mimic C171Q, both unliganded (apo) and with bound TLM at
resolutions ranging between 1.8 and 2.2 A˚ (Table 1). Wild-type
KasA crystallized in space group P3121 with one monomer in
the asymmetric unit, whereas the C171Q variant crystallized in
space group P31 with eight monomers in the asymmetric unit.Structure 17, 1Superposition of the respective monomers within the functional
dimers resulted in a root-mean-square deviation (rmsd) of
0.30 A˚ for the KasA C171Q TLM bound structure and 0.26 A˚ for
the KasA C171Q apo structure, indicating that there are no signif-
icant differences between the monomers within the functional
dimer. The overall structure of KasA is shown in Figure 2. The
homodimeric assembly of the protein in the crystal structures is
consistent with the knowledge that KasA forms a homodimer in
solution. Each monomer is composed of a core domain and
a cap. The core domain can be divided into two halves with similar
topology, a mixed five-stranded b sheet covered on each face by
a helices. Residues 2–259 form the N-terminal half and residues
260–416 the C-terminal half of the protein (Figure 2A). The two
core domains form a five-layered ababa structure characteristic
of the thiolase superfamily, and can be compared with the struc-
tures of other b-ketoacyl ACP synthases (Heath and Rock, 2002;
Mathieu et al., 1994; Olsen et al., 1999; Price et al., 2001). Resi-
dues of the catalytic triad (Cys171, His311, and His345) are
located in the core domain. While the catalytically essential
cysteine that becomes covalently modified during the reaction
is located in the N-terminal domain and lies at the N terminus of
an a helix, all other catalytic residues are contained within the
C-terminal core domain. The more flexible cap consists of helices
a2, a5, and a9, which together with a50 of the second monomer
form the acyl-binding channel (vide infra).
Binding of TLM to Wild-Type KasA
Although the molar protein to TLM ratio for wild-type KasA
complex formation was 1:200, KasA is not fully occupied by
TLM, consistent with the biochemical observation that TLM binds
only weakly to the free enzyme. Nevertheless, the conformation
of the TLM molecule is clearly defined and allows an unambig-
uous assignment of its protein interactions (see Supplemental
Figures available online). TLM binds to the malonyl binding
pocket of KasA. The methyl groups C-9 and C-10 are positioned
in two hydrophobic pockets formed by Pro280, Gly318 and004–1013, July 15, 2009 ª2009 Elsevier Ltd All rights reserved 1005
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Structure of M. tuberculosis KasATable 1. Data Collection and Refinement Statistics
KasA Wild-Type Apo KasA Wild-Type TLM KasA C171Q Apo KasA C171Q TLM
Data Collection
Space group P3121 P3121 P31 P31
Cell dimensions
a, b, c (A˚) 77.53, 77.53, 146.80 77.78, 77.78, 149.52 151.50, 151.50, 147.83 151.27, 151.27, 147.95
a, b, g () 90, 90, 120 90, 90, 120 90, 90, 120 90, 90, 120
Resolution (A˚) 39.55–2.01 (2.08–2.01)a 50.06–1.80 (1.90–1.80) 33.71–2.15 (2.27–2.15) 46.18–2.00 (2.11–2.00)
Rmerge 0.079 (0.338) 0.057 (0.315) 0.080 (0.479) 0.069 (0.348)
<I > / < sI > 9.0 (3.0) 19.1 (7.5) 9.6 (1.6) 14.4 (3.8)
Completeness (%) 99.7 (100) 99.0 (93.2) 97.9 (96.2) 100 (100)
Redundancy 4.4 (4.3) 6.7 (6.5) 1.7 (1.6) 3.9 (3.8)
Refinement
Resolution (A˚) 2.01 1.80 2.15 2.00
Number of reflections 32,867 46,350 280,329 511,630
Rwork/Rfree (%) 18.0 / 21.4 16.7 / 20.1 16.5 / 21.2 13.6 / 17.8
Number of atoms
Protein 3,065 3,096 24,274 24,349
TLM — 14 — 112
PEG — — 98 273
Water 181 281 35 870
B-factors
Protein 40.4 21.1 55.0 29.1
TLM — 26.0 — 29.8
PEG — — 57.7 45.4
Water 43.7 30.7 47.5 29.9
Rmsd
Bond lengths (A˚) 0.012 0.013 0.005 0.011
Bond angles () 1.296 1.421 0.917 1.532
Twin fraction 0.459 0.287
a Values in parentheses are for highest-resolution shell.Phe402, Phe237, respectively, and the intercalation of the isopre-
noid tail into the space between two peptide bonds, namely
Ala279-Pro280 and Gly403-Phe404, further stabilizes the inter-
action. The isoprenoid moiety of TLM points toward an extended
lipophilic pocket where two important water molecules are
present in all structures and stabilize the loop from Asp273 to
Pro280 (Figure 3A). Two strong hydrogen bonds are formed
between the O-1 oxygen and the nitrogens of the active site histi-
dines, His311 and His345 (Figure 3B). Upon binding of TLM to the
active site, Phe404 and the associated loop comprising residues
Phe402-Gly406 are shifted by 0.9 A˚ to avoid clashes with the
inhibitor. Additionally, the main-chain oxygens of Phe402 and
Val278 are rotated away from the TLM molecule. Binding of
TLM to the active site in M. tuberculosis KasA can be compared
with the related Escherichla coli b-ketoacyl ACP synthase I
(ecFabB, 33% sequence identity to KasA) in the presence of
TLM (Protein Data Bank [PDB] code 1fj4; Price et al., 2001)
(Figure 3B). Unexpectedly, the isoprenoid tail of TLM and, most
strikingly, the active site residue Phe404 adopt different confor-
mations. Phe404 acts as a gatekeeper to the adjacent acyl
channel and assumes a closed conformation in both the free
and TLM-bound wild-type KasA structures. This feature has not1006 Structure 17, 1004–1013, July 15, 2009 ª2009 Elsevier Ltd Allbeen observed in the TLM-bound and apo structures of ecFabB,
where the corresponding residue Phe392 is always observed in
an open conformation leading to an almost perpendicular orien-
tation of its aromatic ring relative to the TLM thiolactone ring. In
contrast, the aromatic ring of Phe404 in KasA is oriented parallel
to the thiolactone ring and TLM binding does not appear to alter
the position of Phe404 in KasA, which remains in the ‘‘closed’’
conformation in both wild-type structures.
The Structures of C171Q KasA
Based on the report that the C163Q mutant of E. coli FabF
(ecFabF, b-ketoacyl ACP synthase II, 40% sequence identity to
KasA) mimicked the structural change accompanying acylation
(Wang et al., 2006), we used the C171Q mutant for structural
studies of the intermediate state of KasA. For the C171Q KasA
TLM complex, cocrystallization with a protein to inhibitor ratio of
1:10 led to a structure that was fully occupied with TLM. TLM
forms the same hydrophobic interactions as those described for
the wild-type KasA TLM complex and, likewise, the hydrogen
bonds with the active-site histidines are unchanged (Figure 3C).
However, one fundamental difference is the orientation of the
Phe404 side chain in the C171Q KasA structure. Phe404 adoptsrights reserved
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Structure of M. tuberculosis KasAFigure 2. Overall Structure of Dimeric KasA
(A) One monomer of KasA showing the characteristic thiolase fold. Gray, C-terminal core domain; blue, N-terminal core domain; green, cap. The residues of the
catalytic triad (Cys, His, His) are shown in space-filling representation in light brown.
(B) Dimer of KasA showing the PEG chains in the acyl-binding channels (yellow) and the TLM molecule (black) in space-filling representation.an open conformation, which is also observed in the apo C171Q
KasA structure. The side-chain oxygen of the mutated Gln171
generates a hydrogen bond to the amide nitrogen of Phe404,
thereby shifting the phenylalanine side chain by 60 and by
3.3 A˚ out of the active-site relative to the position of this residue
in the KasA wild-type structure. In this open conformation, the
Phe404 aromatic ring forms an energetically favorable edge-to-
face interaction with the thiolactone ring of TLM (Hunter et al.,
1991). The very flexible loop containing residues Phe402,
Gly403, Gly405, and Gly406, which immediately precede and
follow Phe404, is shifted out of the binding pocket by about
1.5 A˚, while Phe210 and helix a9 are moved away from the cavity
by2 A˚. Thereby the solvent accessible volume of the active-site
cavity is increased from 97 A˚3 in the wild-type to 150 A˚3 in the
mutant structure as calculated with CASTp (Dundas et al.,
2006). Possibly due to additional space in the cavity of the KasA
C171Q mutant, the isoprenoid tail of TLM in the KasA C171Q
structure adopts a different conformation to that observed in the
binary wild-type KasA TLM structure. Calculations of the path-
ways leading from the inside of the pocket to the outside solvent
with CAVER (Petrek et al., 2006) showed that the entrance to the
active site is more restricted in the wild-type enzyme (2 A˚ radius)
than in the mutant (2.5 A˚ radius), suggesting that the binding site is
moreaccessible for TLM, and presumably also the malonyl group,
when the enzyme is acylated (Figure 4). These results support the
contention that replacement of the active site cysteine with
a glutamine mimics structural changes caused by acyl-enzyme
formation. Similar observations are reported for the E. coli FabF
enzyme where Phe400 adopts a closed conformation in the apoStructure 17, 10enzyme but an open conformation in the acyl-enzyme and the
C163Q mutant structures (PDB codes 2gfw, 2gfv, 2gfy and 2gfx
(Wang et al., 2006)). In ecFabF and KasA, this structural rear-
rangement has significant impact on the binding efficiency of
inhibitors. Binding of TLM to C171Q KasA perturbs the protein
structure only very slightly, and just the main-chain oxygen of
Val278 undergoes a significant movement upon TLM binding to
avoid steric clashes with the inhibitor. These structural differences
suggest that the binding pocket is already preformed to accept
the TLM molecule, providing a molecular explanation for the
differential binding behavior of TLM to KasA as observed by
C.A.M. et al. (unpublished data). In this work, direct binding exper-
iments also revealed that addition of TLM to the acyl-enzyme form
of KasA resulted in a much slower decrease in the fluorescence
signal than the instantaneous change observed for the free
enzyme, which suggests that there is a slow-onset component
to the interaction of TLM with acyl-KasA. However, no structural
evidence could be found to explain this phenomenon.
The Acyl Channel of KasA and Substrate Recognition
The acyl channel in KasA is clearly defined in two of our struc-
tures due to the presence of a bound PEG molecule with
a distance of approximately 5.7 A˚ from the active site glutamine
171 and mimics an acyl chain of about 40 carbon atoms in length
(Figures 2B and 5A). These structures thus provide for the first
time a view into the hydrophobic acyl-binding cavity, which is
lined with numerous hydrophobic amino acids and perfectly
accommodates the growing fatty acid chain (Figure 5B). A super-
position with the E. coli FabB structure in complex with a short04–1013, July 15, 2009 ª2009 Elsevier Ltd All rights reserved 1007
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Structure of M. tuberculosis KasA1008 Structure 17, 1004–1013, July 15, 2009 ª2009 Elsevier Ltd Allfatty acid (PDB code 1f91) clearly displays the difference
between proteins capable of binding short versus long fatty
acid chains. Initially the two fatty acids superimpose, but then
the PEG molecule extends through the channel to the surface
of the protein, bends back into the channel, and terminates in
a hydrophobic pocket (Figure 5). In the E. coli structure, side-
chain and backbone atoms from a helix comprising residues
Trp195-Gly205 significantly truncate the acyl-binding channel.
This helix is reoriented in KasA and thereby permits binding of
the longer acyl-chain substrates. Additionally, long polar side
chains point into the channel in E. coli FabB, namely Glu200
and Gln113, as well as Pro110, thereby blocking further access.
In KasA, short hydrophobic side chains Ala209, Ile122, and
Ala119 facilitate fatty acid binding (Figure 5C).
Substrate Binding and Product Release
The acyl channel of KasA is directly accessible through two
openings, the malonyl binding pocket and the opening of the
acyl channel at the surface of the protein. However, migration
of such a long fatty acid chain through the malonyl binding
channel past the hydrophilic and charged active site residues
appears to be energetically and sterically unfavorable. Equally
unfavorable is the migration of the pantetheine group through
the hydrophobic environment of the long acyl channel to the
active site cysteine. Both entries would afford a threading mech-
anism of a long fatty acid, which would be too time-consuming
for efficient transfer between the different enzymes involved in
the individual steps of fatty acid synthesis. A separate mecha-
nism of substrate binding and product release therefore seems
plausible. Comparisons of the wild-type KasA structures with
the C171Q KasA structures indicate that a polypeptide segment
in KasA containing helices a5 and a6 (residues 115–147) shows
increased temperature factors of about 60 A˚2 relative to the
average of the whole protein (40 A˚2) in the wild-type apo KasA
structure. The temperature factors in the respective residues of
the mutant structures remain at the same level as the average.
These findings suggest that this loop remains very flexible in
the absence of a bound acyl substrate and becomes ordered
upon binding of the fatty acid to KasA. It is conceivable that resi-
dues 115–147 move in a concerted way in a scissor like motion
in the dimer, thereby providing direct access to the long acyl
channel (Figure 6). Most likely the opening of the channel is
Figure 3. TLM Binding Sites in Wild-Type KasA, C171Q KasA and
ecFabB
(A) The isoprene side chain of TLM (shown in black all-bonds representation) is
sandwiched between two peptide bonds formed by Ala279-Pro280 and
Gly403-Phe404. Also shown are two water molecules, w1 and w2, in the active
site (blue spheres). Blue dashes indicate hydrogen bonds to the main-chain
atoms of Phe275, His276, Ala279, and Gly405 (purple sticks).
(B) The structure of wild-type KasA with bound TLM (orange with gray TLM)
has been superimposed with the TLM-bound structure of ecFabB (PDB
code 1fj4, shown in blue with black TLM). The green all-bonds representation
indicates the position of Phe404 in the apo wild-type KasA structure. Red
dashes mark the position of hydrogen bonds between TLM and the active
site histidines 311 and 345 in KasA.
(C) The structure of C171Q KasA with bound TLM (colored purple with black
TLM) has been superimposed with the wild-type KasA TLM structure (orange
with gray TLM). Also shown in green all-bonds representation is the structure
of the C163Q mutant of ecFabF, which indicates the position of Phe400 in this
complex (PDB code 2gfx).rights reserved
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Structure of M. tuberculosis KasAfurther guided by the interaction with the acyl carrier protein. Our
findings are further supported by Sachdeva et al. (2008), who
characterized the binding mode of fatty acids to M. tuberculosis
FabH (b-ketoacyl ACP synthase III), and proposed an open
conformational state of FabH where the acyl channel is acces-
sible for acyl substrates or inhibitors.
DISCUSSION
The b-ketoacyl synthase KasA in the M. tuberculosis fatty acid
biosynthesis pathway is a validated but unexploited target for
the development of novel TB chemotherapeutics. In the present
work we have characterized the interaction of KasA with TLM.
Our studies reveal an intricate binding mode of the inhibitor
and direct evidence that explains why the inhibitor is more readily
bound by the acylated rather than the apo enzyme. The presence
of bound PEG molecules provides for the first time insights
regarding how a long-chain fatty acid is accommodated in a
FAS-II enzyme, and rationalizes how it could be efficiently trans-
ferred from one protein to the next in this pathway to yield the
precursors for the essential waxy mycobacterial cell wall.
Comparison of the four crystal structures shows that the main
structural change upon KasA acylation involves a rotation of the
gatekeeper residue Phe404 from a closed to an open conforma-
tion. This observation is based on the presumption that replace-
ment of the catalytic cysteine with a glutamine causes similar
structural changes toKasA thatoccur uponacylation.These struc-
tural changes appear to be driven by the formation of hydrogen
bonds between the oxyanion hole and the carbonyl groups of
either the glutamine side chain or the acyl-enzyme thioester.
Figure 4. Widening of the Malonyl Binding
Pocket in the C171Q KasA Structure
(A) Surface representation of the binding pocket of
the wild-type KasA apo structure. Active-site resi-
dues are shown as sticks.
(B) Binding pocket of wild-type KasA with bound
TLM.
(C) Binding pocket of the C171Q KasA mutant.
(D) Binding pocket of the KasA C171Q mutant with
bound TLM.
Formation of these hydrogen bonds
causes Phe404 to rotate, resulting in an
increase in the size of the malonyl binding
pocket and a widening of the entrance to
the pocket that facilitates TLM binding.
These rearrangements in KasA, combined
with the energetically favorable edge-
to-face interaction between Phe404 and
TLM, provide an explanation for the
increase in affinity of the inhibitor for the
acylated enzyme.
Careful comparison of the C171Q KasA
structures in the apo and inhibitor-bound
state does not reveal any major change
in structure that could account for the
slow-onset component to the inhibition
of the acylated enzyme by TLM. Although
slow-onset inhibition has been observed in a number of systems,
structural explanations for this kinetic phenomenon have only
been elucidated in a few cases and are generally presumed to
involve the formation of a final enzyme-inhibitor complex (EI*)
via a conformational change following formation of the initial EI
complex. In the FAS-II pathway, slow-onset inhibition of the
enoyl-ACP reductase enzyme (FabI, InhA in M. tuberculosis) by
inhibitors such as triclosan leads to ordering of a loop of amino
acids close to the active site (Sivaraman et al., 2003; Stewart
et al., 1999). However, no such structural change is observed
for KasA. Although conversion of EI to EI* in KasA could involve
numerous subtle changes in structure, it is also possible that the
structure of the TLM-bound C171Q KasA corresponds to the
initial EI complex. Further studies are in progress to elucidate
the structural basis for slow-onset inhibition, and to develop
additional TLM analogs that retain this mode of inhibition while
also retaining the ‘‘drug-like’’ properties of the parent molecule.
Previous studies (Kim et al., 2006) aimed toward the modifica-
tion of TLM at the 5 position due to the observation that the
isoprene side chain of TLM is pointing toward a lipophilic pocket,
which could be filled and thereby increase the affinity of the lead
compound. Although this pocket is slightly larger in KasA
compared to homologous enzymes in E. coli, our structures
clearly reveal that this pocket can not accommodate a longer
hydrophobic chain, because two important water molecules
are present in all structures and stabilize the loop from Asp273
to Pro280. Removal of the double bonds in the isoprene side
chain was attempted, but again yielded no improvement of the
lead compound. In the KasA structures, the isoprene side chain
is sandwiched between two peptide bonds. This arrangement
Structure 17, 1004–1013, July 15, 2009 ª2009 Elsevier Ltd All rights reserved 1009
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groups would sterically interfere with either of the two walls
formed by residues 279–280 and 403–404.
On the basis of our crystal structures, we suggest a novel
approach toward improvement of the lead compound TLM. The
bound PEG molecules in our crystal structures directly point
toward the possibility to combine the TLM molecule with a
polyethylene glycol molecule of defined length. This so-called
PEGylation is a common process used to modify drugs or thera-
peutic molecules, mostly to improve solubility and decrease
immunogenicity. Additionally, PEGylation can increase the
stability of the drug and the retention time of the conjugates in
blood, thereby allowing a reduced dosing frequency and reduced
cost (Veronese and Pasut, 2005). In the case of drug develop-
ment against tuberculosis, where current treatment can take
longer than 12 months, this improvement is very desirable. A
PEG chain with a length of 40–50 atoms attached to TLM could
also have the advantage of achieving increased specificity, tar-
geting only the mycobacterial FAS-II enzymes without affecting
the human system that is not able to accommodate such long
substrates. Further studies will prove if a combined TLM-PEG
molecule is able to bind to KasA and trigger the conformational
change of the gatekeeper residue Phe404 to induce the favorable
interaction between the TLM thiolactone ring and the phenylala-
nine side chain.
The binding of long PEG chains in the acyl channels of the
KasA structures allowed us to unambiguously assign the mode
of substrate binding and the residues important for fatty acid
binding. The FAS-II pathway in M. tuberculosis synthesizes fatty
acids with a length of up to C56, in contrast to the much shorter
lipids produced by the FAS-II systems in organisms such as
E. coli. The visualization of a PEG molecule in the acyl channel,
which is truncated in the homologous protein from E. coli,
provides clear insight into how KasA in M. tuberculosis accom-
modates long acyl chains, which can contain up to 56 carbon
atoms, and thereby efficiently build the mycolic acids required
for its cell wall. Previous studies (Sachdeva et al., 2008) on the
mycobacterial enzyme FabH presented the first clues on how
a long acyl chain enters the channel. Our structural analyses
reveal that KasA can adopt a related mechanism. Two helices,
a5 and a6, comprising residues 115–147, are very flexible in
Figure 5. The Acyl Channel inM. tuberculosis KasA and E. coli FabB
Superposition of the acyl-chain-bound ecFabB structure (PDB code 1f91,
green) with C171Q KasA (blue and purple) clearly shows that the fatty acid
of FabB (green all-bonds representation) merges with the PEG molecule
(yellow all-bonds representation) found in the KasA structure.
(A) Surface representation of the acyl-binding channel of KasA with the bound
PEG molecule (yellow all-bonds representation). For clarity, the front part of the
protein is removed to allow a view into the hydrophobic channel.
(B) The acyl channel lies in the interface of the monomers (blue and purple
cartoon). The hydrophobic residues in KasA that line the acyl channel are
shown in all-bonds representation.
(C) Superposition of the KasA acyl channel with the corresponding part of the
ecFabB acyl structure (green ribbon and sticks). The helices and the polar resi-
dues in FabB truncate the acyl binding channel, thus shifting the substrate
specificity to shorter-chain-length fatty acids. The large polar residues in the
FabB structure (Glu200 and Gln113) together with Pro110 (all in green sticks)
that obstruct the channel correspond to small hydrophobic residues in KasA
(Ala209, Ile122, and Ala119, blue sticks).ll rights reserved
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two monomers to accommodate the long fatty acid substrates
in the substrate binding pocket. This movement ensures a facili-
tated uptake and subsequent release of the substrate, thus
allowing an efficient transfer between the different enzymes in
the pathway.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
Wild-type KasA and the C171Q mutant were expressed in Mycobacterium
smegmatis strain mc2155 using the mycobacterial expression vector pFPCA
(Changsen et al., 2003). The plasmid was transformed into M. smegmatis
competent cells by electroporation. Colonies selected on 7H10 solid media
containing 50 mg/ml kanamycin, 200 mg/ml ampicillin, and 10 mg/ml cyclohex-
imide were cultivated in 7H9 liquid media supplemented with 0.5% glycerol
and antibiotics and grown to an optical density (OD600) of 0.6–0.8, and protein
expression was induced with 0.2% acetamide. After 36 hr, cells were har-
vested by centrifugation and frozen at 80C. For purification, cell pellets
were thawed in 20 mM CHES (N-cyclohexyl-2-aminoethanesulfonic acid,
pH 9.5), 500 mM NaCl, and 5 mM imidazole and lysed by sonication. The lysate
was centrifuged and the supernatant applied to a HisTrap HP column (GE
Healthcare). A gradient of 40 mM to 1 M imidazole was used for elution. The
peak fractions were pooled and diluted to reduce the NaCl concentration to
50 mM. The protein solution was applied to a MonoQ 10/100 column (GE
Healthcare) and eluted with a gradient of 50 mM to 1 M NaCl. The fractions
containing the pure protein were applied to a Superdex 26/60 200 size exclu-
sion column (GE Healthcare) that was equilibrated with 20 mM CHES (pH 9.5)
and 500 mM NaCl. Wild-type KasA and the C171Q KasA mutant were concen-
trated to final concentrations of 4.3 mg/ml and 8.5 mg/ml, respectively, before
crystallization.
Crystallization and Structure Determination
KasA was crystallized by vapor diffusion, mixing equal volumes of protein
and precipitant solution. For wild-type KasA, the precipitant contained 10%
Figure 6. Proposed Substrate Binding
Mechanism of KasA
Dimer of the KasA C171Q variant displayed in
blue and gray cartoons. The hypothetical gate
segments (residues 115–147) are shown as
ribbons in red and orange. Arrows indicate the
movement of the gates that is necessary to open
the acyl channel. PEG chains occupying the acyl
channel are shown as yellow and red spheres.
isopropanol, 0.2 M NaCl, 0.1 M HEPES (pH 7.5),
and 10 mM TCEP (tris[2-carboxyethyl] phosphine
hydrochloride). The precipitant solution of the
C171Q KasA crystals contained 20% PEG 3350
and 0.2 M potassium formate. Crystals appeared
after 2 days. For the formation of the KasA inhibitor
complexes, TLM (Sigma) was dissolved in isopro-
panol and added to the concentrated protein solu-
tion, in a molar ratio of 10:1 for the C171Q KasA
variant and 200:1 for wild-type KasA, prior to crys-
tallization. Before cryocooling in liquid nitrogen,
the crystals were briefly transferred into a cryopro-
tectant solution that contained the respective
precipitant and 30% glycerol for the wild-type
KasA crystals and 25% ethylene glycol for the
C171Q KasA crystals. Diffraction data of wild-
type KasA and the C171Q mutant were collected
on a Rigaku MicroMax-007HF generator with an
Raxis HTC Detector. Data sets were processed
using D*Trek implemented in the CrystalClear software (Rigaku). The data
set of the binary C171Q KasA TLM complex was collected at the protein struc-
ture factory beamline BL14.2 at BESSYII, Berlin, and the data set of the binary
wild-type KasA TLM complex was collected at beam line ID14 of the European
Synchrotron Radiation Facility, Grenoble. Both were indexed and integrated
using Mosflm (Leslie, 1992) and scaled with Scala (CCP4, 1994). All structures
were solved by molecular replacement using Phaser (McCoy et al., 2007). As
a search model for the wild-type KasA apo structure, one monomer of the
M. tuberculosis KasB structure (PDB code 2GP6; Sridharan et al., 2007) was
used. For all subsequent structures, the coordinates of the refined wild-type
KasA apo structure were used. Data collection statistics are given in Table 1.
Model Building and Refinement
Model building and refinement of the wild-type KasA structures was carried
out using alternating rounds of COOT (Emsley and Cowtan, 2004) for manual
model building and REFMAC (Murshudov et al., 1997) for maximum likelihood
refinement. The TLM molecule and water molecules were built into the electron
density using COOT. Ramachandran statistics calculated by MolProbity (Davis
et al., 2007) showed that 97.4% of all residues are in the favored region, 99.8%
are in the allowed region, and 1 residue is an outlier in the wild-type KasA struc-
ture. In the wild-type KasA TLM-bound structure, 97.9% of the residues are
in the favored region and 100% are in the allowed region. Due to problems
during refinement of the C171Q KasA structures with REFMAC, a twinning
test with Phenix.xtriage (Zwart et al., 2008) was performed and indicated
that the C171Q KasA TLM data set was merohedrally twinned at 29% and
the C171Q apo KasA data set at 46%. Further refinement was carried out using
Phenix.refine (Adams et al., 2004), taking into account the twin law and refining
the twin fraction. Upon twin refinement, the density improved and the Rfree
decreased, which permitted further model building in COOT and allowed the
unambiguous modeling of TLM, water molecules, and PEG molecules into
the electron density maps. To avoid bias of the Rfree due to the presence of
8-fold NCS and twinning, 5% of all reflections that were omitted during refine-
ment to calculate the Rfree were selected in 20 thin resolution shells. In the
C171Q KasA structure, 95.7% of the residues are in the favored region,
99.6% are in the allowed region, and 13 residues are outliers. The C171Q
KasA TLM-bound structures has 96.7% of the residues in the favored region,
Structure 17, 1004–1013, July 15, 2009 ª2009 Elsevier Ltd All rights reserved 1011
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Structure of M. tuberculosis KasA99.6% in the allowed region, and 12 outliers. Refinement statistics are given in
Table 1. Figures 2–6 were prepared using PyMOL (DeLano, 2002).
ACCESSION NUMBERS
Coordinates for the crystal structures of Mycobacterium tuberculosis KasA,
KasA-TLM, C171Q KasA, and C171Q KasA-TLM have been deposited in the
PDB with accession codes 2wgd, 2wge, 2wgf, and 2wgg, respectively.
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Supplemental Data include two figures and can be found with this article online
at http://www.cell.com/structure/supplemental/S0969-2126(09)00218-4.
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